Partnership collaboration: the SynBio3 technology platform at the heart of innovation
The SynBio3 "polymer platform" technology platform, in collaboration with IBMM's "Polymers for Health and Biomaterials" department, the Montpellier Proteome Cluster and MedinCell, have joined forces for the BIOPOLTRACE project.
Winner of the AAP Plateformes Régionales de Research et d'Innovation (PRRI) 2020, the BIOPOLTRACE project aims to develop new methods for monitoring the in vivo degradation of polymers used in the medical and pharmaceutical fields.As part of the regulatory obligations associated with the marketing of an implantable medical device or an injectable drug, the assessment of the degradation of the materials used, the identification of degradation products and the question of the fate of these degradation products are central to obtaining a CE mark or a marketing authorization.
To date, polymers such as poly(lactic acid) (PLA) and poly(ethylene glycol) (PEG) contained in medical devices and medicines are subject to these obligations. But current methods of monitoring polymer degradation using radioactive or fluorescent probe labeling techniques are limited and have many drawbacks.
BIOPOLTRACE aims to overcome these limitations by monitoring the degradation of PLA-PEG copolymers in vivo using analytical methods such as Maldi-Tof mass spectrometry and liquid chromatography coupled with mass spectrometry (LCMS, LC 2D/MS, SEC, etc.).
In addition, carbon-13 isotopic labelling of the species to be studied will also be used to improve the sensitivity of analytical techniques.